Skip to main content
Top
Published in: Internal and Emergency Medicine 3/2017

01-04-2017 | IM - ORIGINAL

Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension

Authors: Lacedonia Donato, Carpagnano Giovanna Elisiana, Galgano Giuseppe, Schino Pietro, Correale Michele, Natale Daniele Brunetti, Ventura Valentina, Di Biase Matteo, Foschino Barbaro Maria Pia

Published in: Internal and Emergency Medicine | Issue 3/2017

Login to get access

Abstract

In patients with systemic sclerosis, a ratio between forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO, FCV%/DLCO%) >1.5 might be a predictor of pulmonary hypertension (PH). The aim of this study is, therefore, to evaluate whether this index can be used in patients with PH, regardless of etiology. 83 consecutive outpatients with suspected PH at non-invasive work-up underwent spirometry and DLCO test before right heart catheterization (RHC); FVC%/DLCO% ratio was then calculated and compared with mean pulmonary-artery-pressure (mPAP) and mortality at 5-year follow-up. Significant correlations between FVC%/DLCO% and PAsP and mPAP levels were found (p < 0.05). After ROC curve analysis and definition of best cut-off values for PAsP and FVC%/DLCO%, increased mPAP values at RHC were observed comparing subjects with both PAsP and FVC%/DLCO% values below cut off values (−/−), either PAsP or FVC%/DLCO% above cut off values (±), or both above (+/+) (p < 0.05). Poorer survival rates are observed at follow-up with higher FVC%/DLCO% values (0% for <1, 17.4% for 1–3, 33.3% for >3, p < 0.05), when comparing subjects with either increased PAsP and FVC%/DLCO% values or both with those with lower (log-rank p < 0.05). Even in subjects with mPAP at RHC >25 mmHg, increased FVC%/DLCO% values predicted a worse outcome (p < 0.05). FVC%/DLCO% values are related to mPAP in subjects with suspected PH, and may further stratify the risk of mortality in addition to PAP.
Literature
1.
go back to reference Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2015) ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J (pii ERJ-01032-2015) Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2015) ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J (pii ERJ-01032-2015)
2.
go back to reference Iyer AS, Wells JM, Vishin S, Bhatt SP, Wille KM, Dransfield MT (2014) CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest 145:824–832CrossRefPubMed Iyer AS, Wells JM, Vishin S, Bhatt SP, Wille KM, Dransfield MT (2014) CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest 145:824–832CrossRefPubMed
3.
go back to reference Sivova N, Launay D, Wémeau-Stervinou L, De Groote P, Remy-Jardin M, Denis G, Lambert M, Lamblin N, Morell-Dubois S, Fertin M, Lefevre G, Sobanski V, Le Rouzic O, Hatron PY, Wallaert B, Hachulla E, Perez T (2013) Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis. PLoS One 8:e78001CrossRefPubMedPubMedCentral Sivova N, Launay D, Wémeau-Stervinou L, De Groote P, Remy-Jardin M, Denis G, Lambert M, Lamblin N, Morell-Dubois S, Fertin M, Lefevre G, Sobanski V, Le Rouzic O, Hatron PY, Wallaert B, Hachulla E, Perez T (2013) Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis. PLoS One 8:e78001CrossRefPubMedPubMedCentral
4.
go back to reference Sidhu B, Hashemi N, Rashidian A, Sharma S, Gill N, Mills P, Balasubramanian V (2015) Utility of pulmonary function testing in detection of pulmonary arterial hypertension. A58. Clinical evaluation of pulmonary hypertension. p A1875 (First published online 17 Feb 2015) Sidhu B, Hashemi N, Rashidian A, Sharma S, Gill N, Mills P, Balasubramanian V (2015) Utility of pulmonary function testing in detection of pulmonary arterial hypertension. A58. Clinical evaluation of pulmonary hypertension. p A1875 (First published online 17 Feb 2015)
5.
go back to reference Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD (2014) Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS) cohort study. Semin Arthr Rheum 44:55–62CrossRef Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD (2014) Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS) cohort study. Semin Arthr Rheum 44:55–62CrossRef
6.
go back to reference Al Plummer (2008) The carbon monoxide diffusing capacity: clinical implications, coding, and documentation. Chest 134:663–667CrossRef Al Plummer (2008) The carbon monoxide diffusing capacity: clinical implications, coding, and documentation. Chest 134:663–667CrossRef
7.
go back to reference Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003) Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41:1028–1035CrossRefPubMed Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003) Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41:1028–1035CrossRefPubMed
8.
go back to reference Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR, DETECT study group (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340–1349CrossRefPubMed Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR, DETECT study group (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340–1349CrossRefPubMed
9.
go back to reference Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M (2010) Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 29:181–187CrossRefPubMed Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M (2010) Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 29:181–187CrossRefPubMed
10.
go back to reference Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM (2016) Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail 4:441–449CrossRefPubMed Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM (2016) Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail 4:441–449CrossRefPubMed
11.
go back to reference Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease [GOLD] Workshop summary. Am J Resp Crit Care Med 163:1256–1276CrossRefPubMed Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease [GOLD] Workshop summary. Am J Resp Crit Care Med 163:1256–1276CrossRefPubMed
12.
go back to reference Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre M, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948–968CrossRefPubMed Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre M, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948–968CrossRefPubMed
13.
go back to reference Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735CrossRefPubMed Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735CrossRefPubMed
14.
go back to reference Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing Z, Opitz C, Seyfarth H, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer H, Baroke E, Rubin LJ (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48:2546–2552CrossRefPubMed Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing Z, Opitz C, Seyfarth H, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer H, Baroke E, Rubin LJ (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48:2546–2552CrossRefPubMed
15.
go back to reference Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030CrossRefPubMed Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030CrossRefPubMed
16.
go back to reference Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG (2011) Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry. Chest 140:19–26CrossRefPubMedPubMedCentral Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG (2011) Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry. Chest 140:19–26CrossRefPubMedPubMedCentral
17.
go back to reference Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, Chiossig E, Kusic-Pajic A, Simonneau G (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371:2093–2100CrossRefPubMed Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, Chiossig E, Kusic-Pajic A, Simonneau G (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371:2093–2100CrossRefPubMed
18.
go back to reference Meyrick B, Reid L (1983) Pulmonary hypertension. Anatomic and physiologic correlates. Clin Chest Med 4:199–217PubMed Meyrick B, Reid L (1983) Pulmonary hypertension. Anatomic and physiologic correlates. Clin Chest Med 4:199–217PubMed
19.
go back to reference Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003) Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41:1028–1035CrossRefPubMed Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003) Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41:1028–1035CrossRefPubMed
20.
go back to reference Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthr Rheum 35:765–770CrossRef Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthr Rheum 35:765–770CrossRef
21.
go back to reference Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD (2007) Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131:657–663CrossRefPubMed Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD (2007) Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131:657–663CrossRefPubMed
22.
go back to reference Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127:1531–1536CrossRefPubMed Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127:1531–1536CrossRefPubMed
23.
go back to reference Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E (2005) Severe pulmonary hypertension in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189–194CrossRefPubMed Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E (2005) Severe pulmonary hypertension in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189–194CrossRefPubMed
24.
go back to reference Weitzenblum E, Chaouat A (2005) Severe pulmonary hypertension in COPD: is it a distinct disease? Chest 127:1480–1482CrossRefPubMed Weitzenblum E, Chaouat A (2005) Severe pulmonary hypertension in COPD: is it a distinct disease? Chest 127:1480–1482CrossRefPubMed
25.
go back to reference Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE (2002) Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166:314–322CrossRefPubMed Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE (2002) Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166:314–322CrossRefPubMed
26.
go back to reference Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Carpentier C, Kessler R (1995) Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 107:1193–1198CrossRefPubMed Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Carpentier C, Kessler R (1995) Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 107:1193–1198CrossRefPubMed
27.
go back to reference D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT (1991) Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115:343–349CrossRefPubMed D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT (1991) Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115:343–349CrossRefPubMed
28.
29.
go back to reference Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M (2010) Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 29:181–187CrossRefPubMed Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M (2010) Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 29:181–187CrossRefPubMed
30.
go back to reference Marini C, Formichi B, Bauleo C, Michelassi C, Pancani R, Prediletto R, Miniati M, Catapano G, Monti S, Mannucci F, Tavoni A, D’Ascanio A, Pastormerlo LE, Giannoni A, Giuntini C (2014) Improved survival in limited scleroderma-related pulmonary artery hypertension. Intern Emerg Med 9:385–396CrossRefPubMed Marini C, Formichi B, Bauleo C, Michelassi C, Pancani R, Prediletto R, Miniati M, Catapano G, Monti S, Mannucci F, Tavoni A, D’Ascanio A, Pastormerlo LE, Giannoni A, Giuntini C (2014) Improved survival in limited scleroderma-related pulmonary artery hypertension. Intern Emerg Med 9:385–396CrossRefPubMed
31.
go back to reference Marini C, Formichi B, Bauleo C, Michelassi C, Airò E, Rossi G, Giuntini C (2016) Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension. Intern Emerg Med 11:941–952CrossRefPubMed Marini C, Formichi B, Bauleo C, Michelassi C, Airò E, Rossi G, Giuntini C (2016) Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension. Intern Emerg Med 11:941–952CrossRefPubMed
Metadata
Title
Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension
Authors
Lacedonia Donato
Carpagnano Giovanna Elisiana
Galgano Giuseppe
Schino Pietro
Correale Michele
Natale Daniele Brunetti
Ventura Valentina
Di Biase Matteo
Foschino Barbaro Maria Pia
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 3/2017
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-016-1573-9

Other articles of this Issue 3/2017

Internal and Emergency Medicine 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.